https://orcid.org/0000-0001-6279-3489
References
- Makragiannis G, Vahdani K, Carreño E, Lee R, Dick A, Ross A. Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. Int Ophthalmol. 2018;38(2):781–785. doi:10.1007/s10792-017-0502-x.
- Jampol, Sung J, Walker J, et al. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am J Ophthalmol. 1996;121(6):643–649. doi:10.1016/S0002-9394(14)70630-0.
- Invernizzi A, Cozzi M, Symes R, Pellegrini M, Staurenghi G. Ocular neovascularization in endogenous Candida endophthalmitis: using multimodal imaging to understand different pathogenic pathways. Retina. 2018. doi:10.1097/IAE.0000000000001978.
- Kianersi F, Naderi Beni A, Naderi Beni Z, Ghanbari H. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series. Semin Ophthalmol. 2015;30(3):181–187. doi:10.3109/08820538.2013.838278.
- Lyall D, Hutchison B, Gaskell A, Varikkara M. Intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye (Lond). 2010;24:1730–1731. doi:10.1038/eye.2010.131.